Merck collaborates on new monoclonal antibody and process technology offering

Merck has announced a collaborative project that will see the company introduce a new integrated end-to-end offering for drug manufacturing.

The company is allying with IPS-Integrated Project Services and G-CON Manufacturing to provide advanced 2,000L monoclonal antibody facilities and a single-use process technology platform.

This partnership will extend Merck's BioReliance End-to-End offering by integrating the firm's single-use process equipment, end-to-end process development capabilities and cGMP manufacturing experience into the iCON facility design platform.

It is intended that this combination will facilitate the fast and flexible deployment of new high-calibre production facilities, offering prefabricated cleanroom units, a structural platform based on pre-engineered building delivery, bioprocess and single-use equipment expertise, and turnkey facilities capable of fast-track deployment.

Andrew Bulpin, head of the process solutions business for Merck's life science division, said: "This collaboration is an innovative concept built upon Merck's years of experience in designing, constructing and running cGMP biologics production, combined with the iCON facility, team and design platform."

With over 20 years of experience within the science market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current science roles we have available, you can search for the latest job roles, register your details, or contact the team today.